With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 9590.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.6173 whereas the lowest price it dropped to was $12.1. The 52-week range on PTN shows that it touched its highest point at $72.50 and its lowest point at $1.75 during that stretch. It currently has a 1-year price target of $350.00. Beta for the stock currently stands at 0.09.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PTN was up-trending over the past week, with a rise of 111.30%, but this was up by 286.78% over a month. Three-month performance surged to 114.07% while six-month performance rose 300.35%. The stock lost -58.88% in the past year, while it has lost -50.92% so far this year.
Float and Shares Shorts:
At present, 1.70 million PTN shares are outstanding with a float of 1.58 million shares on hand for trading. On 2025-04-30, short shares totaled 38596.0, which was 676.0000400000001 higher than short shares on 1743379200. In addition to Dr. Carl Spana Ph.D. as the firm’s Co-Founder, President, CEO & Director, Mr. Stephen T. Wills CPA, MST serves as its CFO, COO, Executive VP, Treasurer & Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, PTN reported revenue of $8847550.0 and operating income of $4661053.0. The EBITDA in the recently reported quarter was $4675440.0 and diluted EPS was $4.26.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PTN since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.51205 being high and -$2.51205 being low. For PTN, this leads to a yearly average estimate of -$2.51205. The surprise factor in the prior quarter was -$21.
